期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征一例 被引量：2

原文传递
导出
摘要 患者男，71岁，确诊骨髓增生异常综合征一转化中的难治性贫血伴原始细胞增多（MDS-RAEB-t）26个月。患者于2008年10月发病，当时血常规：WBC2×10^6／L，Hb126g／L，Plt103×10^9／L，骨髓增生低下，原始粒细胞0．17，免疫分型：
作者 张姗姗 唐旭东 刘锋
机构地区 中国中医科学院西苑医院血液科
出处 《白血病．淋巴瘤》 CAS 2012年第8期510-511,共2页 Journal of Leukemia & Lymphoma
关键词 药物疗法 联合 骨髓增生异常综合征
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献11

  • 1Rosu-Myles M, Wolff L. p15 Inkdb: dual function in myelopoiesis andinactivation in myeloid disease. Blood Cells Mol Dis, 2008, 40: 406,-409.
  • 2de Vos D, van Overveld W. Decitabine: a historical review of the development of an ep igenetic drug. Ann Hematol, 2005, 84: 328.
  • 3Wang Y, Leung FC. An evaluation of new criteria for CpG is lands in the human genome as gene markers. Bioinformaties, 2004, 20:1170-1177.
  • 4Rmermann D, Hasemeier B, Metzig K, et al. Global in crease in DNA methylation in patients with myelodysplastic syndrome.Leukemia, 2008, 22: 1954-1956.
  • 5Momparler RL. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). Sem Hematol, 2005, 42: 9216.
  • 6Gautam B, Samihea, Farhad R, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leukemia & Lymphoma, 2008, 49: 690-695.
  • 7David PS, Richard MS. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin N Am, 2010, 24: 389-406.
  • 8Steensma DP, Baer MR, Slack JL, et al. Muhicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment(ADOPT) trial. J Clin Oncol, 2009, 27: 3849-3848.
  • 9贡蓉,乔振华,王雁玲,秦彦.地西他滨治疗高危骨髓增生异常综合征二例疗效观察[J].中国药物与临床,2010,10(7):825-827. 被引量：9
  • 10高冲,陈宝安,刘苒,徐昕,丁家华,王骏,程坚,赵刚,余正平,宋慧慧,鲍文.地西他滨治疗骨髓增生异常综合征一例报告[J].现代医学,2010,38(2):189-190. 被引量：10

二级参考文献14

  • 1夏瑞祥,蔡学杰.地西他滨在恶性血液病中的作用[J].安徽医药,2006,10(12):900-901. 被引量：4
  • 2WIJERMANS P,LUBBERT M,VERHOEF G,et al.Low-dose5-Aza-2'-deoxycytidine,a DNA hypomethylating agent,for the treatment of high-risk myelodysplastic syndrome:A multicenter phase Ⅱ study in elderly patients.Ann Hematol,2005,84(Suppl 13):9-17.
  • 3WIJERMANS P W,LUBBERT M,VERHOEF G,et al.An epigenetic approach to the treatment of advanced MDS;the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine(decitabine) in 177 patients[J].Ann Hematol,2005,84(Suppl 13):9-17.
  • 4Vardiman JW,Thiele J,Arber DA,et al.The 2008 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia:rationale and important changes.Blood,2009,114:937-951.
  • 5Babicka L,Ransdorfova S,Brezinova J,et al.Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH.Leuk Res,2007,31:39-47.
  • 6Steensma DP,Baer MR,Slaek JL,et al.How I treat patients with myelodysplastic syndromes.Blood,2009,113:6296-6303.
  • 7Oki Y,Aoki E,Issa JP,et al.Decitabine-Bedside to bench.Crit Rev Oncol Hematol,2007,61:140-152.
  • 8Gryn J,Zeigler ZR,Shadduck RK,et al.Treatment of myelodysplastic syndromes with 5-azacytidine.Leuk Res,2002,26:893-897.
  • 9O'Brien SM,Ravandi-kashani F,Gile S,et al.Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS):Comparison of 3 different dose schedules.J Clin Oncol,2005,23:571s.
  • 10Lubbert M,Wijerman S P,Kunzmann R,et al.Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.Br J Haematol,2001,114:349-357.

共引文献17

同被引文献19

  • 1Morrow G,Tanguay RM.Small heat shock protein expression and functions during development.Int J Biochem Cell Biol,2012,44:1613-1621.
  • 2Kampinga HH,Garrido C.HSPBs:small proteins with big implications in human disease.Int J Biochem Cell Biol,2012,44:1706-1710.
  • 3Shemetova A,Seit-Nebia S,Gusev NB.Structure,properties,and functions of the human small heat-shock protein HSP22 (HspB8,H11,E2IG1):a critical review.J Neurosci Res,2008,86:264-269.
  • 4Hu Z,Chen L,Zhang J,et al.Structure,function,property,and role in neurologic diseases and other diseases of the sHsp22.J Neurosci Res,2007,85:2071-2079.
  • 5Smith CC,Yu YX,Kulka M,et al.A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells.J Biol Chem,2000,275:25690-25699.
  • 6Benndorf R,Sun X,Gilmont RR,et al.HSP22,a new member of the small heat shock protein superfamily,interacts with mimic of phosphorylated HSP27 ((3D)HSP27).J Biol Chem,2001,276:26753-26761.
  • 7Gober MD,Smith CC,Ueda K,et al.Forced expression of the H11 heat shock protein can be regulated by DNA methylation and trigger apoptosis in human cells.J Biol Chem,2003,278:37600-37609.
  • 8Li B,Smith CC,Laing JM,et al.Overload of the heat-shock protein H1 1/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1.Oncogene,2007,26:3521-3531.
  • 9Trent S,Yang C,Li C,et al.Heat shock protein B8,a cyclindependent kinase-independent cyclin D 1 target gene,contributes to its effects on radiation sensitivity.Cancer Res,2007,67:10774-10781.
  • 10Yang C,Trent S,Ionescu-Tiba V,et al.Identification of cyclin D1-and estrogen-regulated genes contributing to breast carcinogenesis and progression.Cancer Res,2006,66:11649-11658.

引证文献2

二级引证文献1

白血病．淋巴瘤
2012年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部